Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Millennium Gets Corey Chemistry

June 7, 2004 | A version of this story appeared in Volume 82, Issue 23

Millennium Pharmaceuticals has signed a research agreement with Harvard University and Harvard chemistry professor E. J. Corey. Under the deal, Harvard has granted Millennium rights to intellectual property for a family of proteasome inhibitors made with a chemical synthesis developed by Corey. Millennium will pay milestone fees and royalties to Harvard on sales of products resulting from the deal. Millennium won approval for the first proteasome-inhibiting drug, the blood cancer treatment Velcade (bortezomib), about a year ago.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.